Stock 2315 BIOCYTOGEN PHARMACEUTICALS (BEIJING) CO., LTD.
Add to a list
To use this feature you must be a member
Log inSign up

Ratings Biocytogen Pharmaceuticals (Beijing) Co., Ltd.

Equities

2315

CNE100005D27

End-of-day quote Hong Kong S.E.
Other stock markets
 06:00:00 2024-07-10 pm EDT 		5-day change 1st Jan Change
7.59 CNY +1.88% Intraday chart for Biocytogen Pharmaceuticals (Beijing) Co., Ltd. +1.61% -36.64%
Jun. 04 XtalPi Inc. announced that it has received CNY 337 million in funding from Shanghai Guosheng Investment Group, Biocytogen Pharmaceuticals Co., Ltd., FaaS Capital Longevity Limited and other investors CI
May. 06 Biocytogen Enters into Evaluation and Potential Licensing Agreement with Biocopy for TCR-mimic Antibodies CI

Summary

  • The company has strong fundamentals. More than 70% of companies have a lower mix of growth, profitability, debt and visibility.

Strengths

  • According to sales estimates from analysts polled by Standard & Poor's, the company is among the best with regard to growth.
  • For the past year, analysts covering the stock have been revising their EPS expectations upwards in a significant manner.
  • The difference between current prices and the average target price is rather important and implies a significant appreciation potential for the stock.
  • The divergence of price targets given by the various analysts who make up the consensus is relatively low, suggesting a consensus method of evaluating the company and its prospects.

Weaknesses

  • Low profitability weakens the company.
  • For the last twelve months, the trend in sales revisions has been clearly going down, which emphasizes downgraded expectations from the analysts.
  • The average price target of analysts who are interested in the stock has been significantly revised downwards over the last four months.
  • Over the past twelve months, analysts' opinions have been revised negatively.
  • The group usually releases earnings worse than estimated.

Ratings chart - Surperformance

Sector: Biotechnology & Medical Research

1st Jan change Capi. Investor Rating ESG Refinitiv
BIOCYTOGEN PHARMACEUTICALS (BEIJING) CO., LTD. Stock Biocytogen Pharmaceuticals (Beijing) Co., Ltd.
-36.64% 388M -
MODERNA, INC. Stock Moderna, Inc.
+23.50% 47.07B
B-
LONZA GROUP AG Stock Lonza Group AG
+47.87% 42.06B
A
IQVIA HOLDINGS INC. Stock Iqvia Holdings Inc.
-5.16% 39.98B
B
ALNYLAM PHARMACEUTICALS, INC. Stock Alnylam Pharmaceuticals, Inc.
+36.37% 33.02B
B
CELLTRION, INC. Stock Celltrion, Inc.
-7.79% 27.9B
C
ICON PUBLIC LIMITED COMPANY Stock ICON Public Limited Company
+18.06% 27.63B
B-
UNITED THERAPEUTICS CORPORATION Stock United Therapeutics Corporation
+47.29% 14.37B
B+
MEDPACE HOLDINGS, INC. Stock Medpace Holdings, Inc.
+41.91% 13.45B
C+
BIO-TECHNE CORPORATION Stock Bio-Techne Corporation
-1.02% 12.03B
B+
Investor Rating
Trading Rating
ESG Refinitiv
-

Financials

Sales growth
Earnings Growth
-
EBITDA / Sales
Profitability
Finances

Valuation

P/E ratio
-
EV / Sales
Price to Book
-
Price to Free Cash Flow
-
Yield
-

Momentum

1 year Revenue revision
4 months Revenue revision
7 days Revenue revision
1 year EPS revision
4 months EPS revision

Consensus

Analyst Opinion
Potential Price Target
4m Target Price Revision
4m Revision of opinion
12m Revision of opinion

Business Predictability

Analyst Coverage
Divergence of Estimates
-
Divergence of analysts' opinions
-
Divergence of Target Price
Earnings quality

Technical analysis

ST Timing
-
MT Timing
-
LT Timing
-
RSI
Bollinger Spread
Unusual volumes
  1. Stock Market
  2. Equities
  3. 2315 Stock
  4. Ratings Biocytogen Pharmaceuticals (Beijing) Co., Ltd.